Coherus Oncology(NASDAQ) CHRS

Market Cap$219.39M

Since IPO (2014)-89%

5 Year-91%

1 Year+26%

1 Month-1%

Premium Feature

Moneyball Superscore

50/100

$1.41

+6.82%

+0.09Today

After hours$1.42+$0.01 (+0.36%)

Coherus Oncology last closing stock price
Metric	Price	Date
Last close	USD 1.42	2026-08-21

Coherus Oncology stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+18.33%	USD 1.20	2026-08-14
1 month	-0.7%	USD 1.43	2026-07-22
3 month	-11.8%	USD 1.61	2026-05-22
Year to date	+0%	USD 1.42	2025-12-31
1 year	+25.66%	USD 1.13	2025-08-21
3 year	-69.4%	USD 4.64	2023-08-22
5 year	-90.53%	USD 15.00	2021-08-20
Since inception	-88.74%	USD 12.61	2014-11-06

Coherus Oncology Financials at a Glance

Market Cap

$219.39M

Revenue (TTM)

$50.94M

Net Income (TTM)

-$130.96M

EPS (TTM)

-$1.02

P/E Ratio

-1.39

Dividend

$0.00

Beta (Volatility)

1.65 (High)

Dividend

$0.00

Beta (Volatility)

1.65 (High)

Price

$1.41

Volume

1,567,515.546

Open

$1.32

Price

$1.41

Volume

1,567,515.546

Open

$1.32

Previous Close

$1.42

Daily Range

$1.32 - $1.44

52-Week Range

$1.09 - $2.62

Estimated Earnings Date

Nov 5, 2026

Dividend

$0.00

Beta (Volatility)

1.65 (High)

Price

$1.41

Volume

1,567,515.546

Open

$1.32

Previous Close

$1.42

Daily Range

$1.32 - $1.44

52-Week Range

$1.09 - $2.62

Estimated Earnings Date

Nov 5, 2026

CHRS News

Page 1

CHRS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Coherus Oncology

Coherus Oncology, Inc. makes medicines that help the body fight cancer. These drugs help patients with rare tumors found in the throat. They use immunotherapy to help the immune system attack cancer cells.

Medicines Fighting Rare Cancers

LOQTORZI: Approved antibody that treats nasopharyngeal cancer, a rare cancer of the nose and throat; generated $13.6 million in net revenue during the second quarter of 2026.
Casdozokitug: Investigational treatment for liver and lung cancers currently being evaluated in a phase two clinical study to test its effectiveness.
Tagmokitug: Experimental antibody designed to clear away specific immune cells that shield tumors from the body's natural defenses.

Strategic Deals and Pipeline Moves

Entered a collaboration with Junshi Biosciences on Feb. 1, 2021, to develop and sell LOQTORZI in North America.
Launched LOQTORZI in the United States on Jan. 2, 2024, following approval from the Food and Drug Administration.
Signed a clinical supply agreement with Janssen Research & Development, LLC, on Feb. 4, 2026, for combination therapy trials.
Exited the biosimilar business in 2025 to focus resources entirely on innovative oncology treatments.

Why the Company Is Unique

Coherus operates as a fully integrated oncology company that manages drug research, manufacturing oversight, and commercial sales. The company maintains global rights to its clinical stage candidates while using international partnerships to expand its reach.

Key Figures for the Business

Total net revenue reached $14.3 million in the three-month period ended June 30, 2026.
Cash, cash equivalents, and marketable securities totaled $105.3 million as of June 30, 2026.
Market cap was $216.7 million in the second quarter of 2026, up 155.3% year over year.
Research and development expenses fell to $21.4 million in the second quarter of 2026.

How the Business Has Evolved

Coherus has transitioned from a producer of biosimilars to a focused oncology company centered on its approved immunotherapy. This shift allows the firm to concentrate its research and capital on developing novel treatments for solid tumors.

AI Generated • Aug 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

147

CEO

Denny M. Lanfear, MBA

Website

www.coherus.com

Headquarters

Redwood City, CA 94065, US

CHRS Financials

Key Financial Metrics (TTM)

Gross Margin

63.55%

Operating Margin

-307.43%

Net Income Margin

-257.10%

Return on Equity

-181.73%

Return on Capital

-177.14%

Return on Assets

-68.50%

Earnings Yield

-71.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$219.39M

Shares Outstanding

154.50M

Volume

1.57M

Avg. Volume

1.01M

Financials (TTM)

Gross Profit

$32.37M

Operating Income

-$156.60M

EBITDA

-$148.46M

Operating Cash Flow

-$243.92M

Capital Expenditure

$0.00

Free Cash Flow

-$243.92M

Cash & ST Invst.

$105.31M

Total Debt

$37.71M

Coherus Oncology Performance Analysis

Coherus Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 211,042,000	-35.4%
2023	2023-12-31	USD 257,244,000	21.9%
2024	2024-12-31	USD 26,389,000	-89.7%
2025	2025-12-31	USD 42,172,000	59.8%

Coherus Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	12.8%
Q4	2025-12-31	10.2%
Q1	2026-03-31	-3.4%
Q2	2026-06-30	16.2%

Coherus Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -3.76	-1.2%
2023	2023-12-31	USD -2.53	-32.8%
2024	2024-12-31	USD -1.29	-48.8%
2025	2025-12-31	USD -1.45	12.5%

Coherus Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	23.1%
Q4	2025-12-31	-3.3%
Q1	2026-03-31	9.7%
Q2	2026-06-30	53.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$14.31M

+39.5%

Gross Profit

$10.07M

+72.3%

Gross Margin

70.35%

N/A

Market Cap

$219.39M

N/A

Market Cap/Employee

$1.52M

N/A

Employees

144

N/A

Net Income

-$20.63M

+50.1%

EBITDA

-$30.16M

+27.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$105.31M

-55.7%

Total Debt

$37.71M

-8.1%

Accounts Receivable

$14.25M

-88.1%

Inventory

$5.67M

+25.6%

Long Term Debt

$37.71M

-4.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

-68.50%

N/A

Return on Invested Capital

-1.35%

N/A

Free Cash Flow

-$119.98M

-157.3%

Operating Cash Flow

-$119.98M

-157.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TARAProtara Therapeutics, Inc.

TARAProtara Therapeutics, Inc.$3.85-1.28%

CDXSCodexis, Inc.

CDXSCodexis, Inc.$1.67+5.70%

IVVDInvivyd, Inc.

IVVDInvivyd, Inc.$1.00+4.81%

IMDXInsight Molecular Diagnostics Inc.

IMDXInsight Molecular Diagnostics Inc.$4.34+0.93%

CCCCC4 Therapeutics, Inc.

CCCCC4 Therapeutics, Inc.$4.00-0.74%

OABIOmniAb, Inc.

OABIOmniAb, Inc.$4.33+0.70%

AVTXAvalo Therapeutics, Inc.

AVTXAvalo Therapeutics, Inc.$19.83+0.05%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.77+0.10%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$43.68+0.06%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.41+0.06%

MARAMara Holdings

MARAMara Holdings$11.26+0.01%

NVDANvidia

NVDANvidia$214.72-0.01%

INTCIntel

INTCIntel$90.07-0.02%

MRNAModerna

MRNAModerna$145.13+0.09%

Questions About CHRS

What is the current price of Coherus Oncology?

Coherus Oncology is trading at $1.42 per share.

What is the 52-week range for Coherus Oncology?

Over the past 52 weeks, Coherus Oncology has traded between $1.09 and $2.62.

How much debt does Coherus Oncology have?

As of the most recent reporting period, Coherus Oncology reported total debt of $54.18M.

How much cash does Coherus Oncology have on hand?

Coherus Oncology reported $82.92M in cash and cash equivalents in its most recent financial results.

What is Coherus Oncology’s dividend yield?

Coherus Oncology does not currently have a dividend yield.

Coherus Oncology(NASDAQ) CHRS

Coherus Oncology Financials at a Glance

CHRS News

Coherus (CHRS) Q2 Revenue Jumps 10%

Why Coherus Biosciences Stock Tumbled on Thursday

Why Coherus BioSciences Stock Jumped Today

Why Coherus BioSciences Stock Is Sinking Today

Why Coherus Biosciences Popped Today

Why Coherus BioSciences Stock Jumped Today

Why Coherus BioSciences Was Plummeting This Week

Why Coherus Biosciences Stock Dropped Today

CHRS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Coherus Oncology

Medicines Fighting Rare Cancers

Strategic Deals and Pipeline Moves

Why the Company Is Unique

Key Figures for the Business

How the Business Has Evolved

CHRS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Coherus Oncology Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CHRS

What is the current price of Coherus Oncology?

What is the 52-week range for Coherus Oncology?

How much debt does Coherus Oncology have?

How much cash does Coherus Oncology have on hand?

What is Coherus Oncology’s dividend yield?

Premium Investing Services